FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer

(MedPage Today) — An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic castration-resistant prostate cancer…

Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/115713

Author :

Publish date : 2025-05-22 13:41:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer

FDA Advisory: Daratumumab Wins, Glofitamab Loses

Doc Gets 10 Years for Fake Diagnoses; Nurse Accused of Removing Mom’s Breathing Tube

Related Posts

‘There’s No Conspiracy’: An Inside Look at CDC’s Key Vaccine Safety Database

A Look at the Phase II SAGA Data for Gildeuretinol in Geographic Atrophy

AI Passes Gastro Board Exam; ALD Hospitalizations Surge; Post-Colonoscopy CRCs

The surprising benefits of breathing through your nose

Doc Gets 10 Years for Fake Diagnoses; Nurse Accused of Removing Mom’s Breathing Tube

FDA Advisory: Daratumumab Wins, Glofitamab Loses

‘There’s No Conspiracy’: An Inside Look at CDC’s Key Vaccine Safety Database

A Look at the Phase II SAGA Data for Gildeuretinol in Geographic Atrophy

AI Passes Gastro Board Exam; ALD Hospitalizations Surge; Post-Colonoscopy CRCs

The surprising benefits of breathing through your nose

Doc Gets 10 Years for Fake Diagnoses; Nurse Accused of Removing Mom’s Breathing Tube

FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer

FDA Advisory: Daratumumab Wins, Glofitamab Loses

Texas Vaccine Surge; Biden Health Investigation; Cocaine Vaccine?

Categories

Archives